Shionogi-Backed Apnimed Seeks $160 Million in US IPO
Apnimed Inc., a clinical-stage biopharmaceutical company backed by Shionogi, is planning a US initial public offering with a target raise of up to $160 million. The company specializes in developing late-stage drug candidates for sleep apnea treatment. This IPO represents a significant funding milestone for the sleep apnea-focused developer.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- BloombergTrace: Center
Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
Apnimed Inc., a clinical-stage biopharmaceutical company backed by Shionogi, is planning a US initial public offering with a target raise of up to $160 million. The company specializes in developing late-stage drug candidates for sleep apnea treatment. This IPO represents a significant funding milestone for the sleep apnea-focused developer.
Rate outletRead original
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.
Trending